---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-270979"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-22T23:58:10.137092+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agios sells TIBSOVO royalty rights to Sagard for $131.8M upfront

## Summary
- Upfront cash payment of $131.8M for 5% royalty on U.S. net sales of TIBSOVO (ivosidenib).
- Agios retains $200M milestone for vorasidenib and 15% royalties on its U.S. net sales.
- Deal provides non-dilutive capital to fund PYRUKYND launch and ongoing pipeline programs.
- Transaction closed on October 27, 2022.

## SEC filing metadata
- accession: 0001193125-22-270979
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312522270979/0001193125-22-270979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312522270979/d409394d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-270979
- JSON: https://secwatch.observer/filing/0001193125-22-270979.json
- Plain text: https://secwatch.observer/filing/0001193125-22-270979.txt

## Key facts
- Material Agreements
  AGIOS PHARMACEUTICALS, INC. entered into Purchase and Sale Agreement with Sagard Healthcare Royalty Partners, LP, Sagard Healthcare Partners Co-Invest Designated Activity Company valued at $131,783,241 (effective 2022-10-27).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Sagard Healthcare Royalty Partners, LP, Sagard Healthcare Partners Co-Invest Designated Activity Company
  - Value: $131,783,241
  - Effective: 2022-10-27
  source text: On October 27, 2022, Agios Pharmaceuticals, Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempt limited partnership, and Sagard Healthcare Partners Co-Invest Designated Activity Company, a company incorporated in Ireland, as purchasers (together, the “Purchasers”), and Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempt limited partnership, as the Purchaser’s representative.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312522270979/0001193125-22-270979-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.